Educational Programmes

The Educational Programmes on this page cover the following items:

Useful resources

GI CONNECT review paper published in Tumor Biology

Four GI CONNECT members authored a paper which looks to the future for circulating tumor DNA in colorectal cancer. ‘Future perspectives of circulating tumor DNA in colorectal cancer’ The paper is published in Tumor Biology and can be viewed here

Go to Programme

GI CONNECT review paper published in Cancer Treatment Reviews

Three GI CONNECT members authored a paper ‘Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer’ with the aim to reconsider the evidence for clinical benefit of intermittent versus continuous treatment in the maintenance treatment setting of mCRC and to evaluate the effect of RAS and BRAF mutational status on maintenance strategies.

Go to Programme

GI CONNECT review paper published in Annals of Oncology

Four GI CONNECT members authored a paper ‘Challenging Chemoresistant Metastatic Colorectal cancer: therapeutic strategies from the clinic and from the laboratory’ with the aim to review the effective and well-tolerated third-line and subsequent lines of treatment; and to exploit oncogenic drivers of colorectal cancer and overcome acquired resistance.

Go to Programme

Overview on Tumor Immunology in CRC

Prof. Franck Pagès from Laboratory of Immunology, Hôpital Européen Georges Pompidou in Paris (France) provides an overview on Tumor Immunology in colorectal cancers.

Go to Programme

Review paper published in Annals of Oncology

Go to Programme

External Resource

Management of Skin Toxicities from MKI Therapies

GI CONNECT has identified this resource as a practical guidance on how to prevent and treat skin toxicities with MKIs. Please click on this link to read the information which you can use for your own purposes.

Go to Programme

External Resource

Drug-Drug Interactions with Kinase Inhibitors

GI CONNECT has identified this resource as a practical guidance on the management of MKI-associated drug-drug interactions. Please click on this link to read the information which you can use for your own purposes.

Go to Programme

Resource

Immunotherapies in mCRC

Associate Professor Dr. Gerald Prager, from the Medical University of Vienna (Austria) has summarised the insights from clinical data on immunotherapies in mCRC for you. Please click on this link to download the slides.

Go to Programme

Resource

Rational to target immune checkpoints in diseases

Dr. Clémence Granier from the Hôpital Européen Georges Pompidou in Paris (France) provides an overview on the rational to target immune checkpoints in various diseases. Please click on this link to download the slides.

Go to Programme

Resource

Salvage therapy to manage liver disease in mCRC

Dr. Cristina Nadal, Medical Oncologist specialised in CRC at the the Hospital Clinic of Barcelona and Associate Professor at the University of Barcelona (Spain) summarised the information and provides practical guidance on the treatment of liver metastases in CRC. Please click on this link to download the slides.

Go to Programme

Resource

Loco regional treatments on colorectal cancer liver metastases

Dr. Fernando Gómez from the Vascular and Interventional Radiology Department of Hospital Clinic de Barcelona (Spain) provides an overview and practical guidance on loco-regional treatment of liver metastases of CRC. Please click on this link to download the slides.

Go to Programme

GI CONNECT Update from…

Your clinical questions answered

Please submit your clinical topic for the next GI CONNECT newsletter here.

KRAS mutant colorectal cancer: the now and the next

Dr. Shubham Pant discussed the Clinical Question: How to treat KRAS mutant colorectal cancer: the now and the next

Go to Programme

What is the role of adding aspirin in PIK3CA mutated patients?

The Clinical Question: What is the role of adding aspirin in PIK3CA mutated patients? has been discussed by Assoc. Prof. Gerald Prager and Prof. David Tougeron.

Go to Programme

Is it time to re-challenge anti-EGFR in mCRC?

The Clinical Question: Is it time to re-challenge anti-EGFR in mCRC? has been discussed by Assoc. Prof. Gerald Prager, Dr. Dominik Modest and Dr. Andrea Sartore-Bianchi.

Go to Programme

Does location matter in colorectal cancer: left vs right?

Dr. Andrea Sartore-Bianchi, Dr. Sebastian Stintzing and Dr. Dominik Modest debate the question, “Does location matter in colorectal cancer: left vs right?”

Go to Programme

How to treat patients after failure on triplet therapy +/- bev?

Dr. Chiara Cremolini, Dr. Erika Martinelli and Dr. Dominik Modest discuss the Clinical Question: How to treat patients after failure on triplet therapy +/- bev? Please click on this link to see the video-introduction and download the slides that you can use for your own purposes.

Go to Programme

Biomarkers: when to test, what to test and what are the consequences?

Dr. Thomas Winder, Dr. Andrea Sartore-Bianchi and Dr. Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences? Please click on this link to see the video-introduction and download the slides that you can use for your own purposes.

Go to Programme

When to test for BRAF and what are the consequences?

Dr. Chiara Cremolini, Dr. Armin Gerger, Dr. Guillem Argilés discuss the Clinical Question: When to test for BRAF and what are the consequences?

Go to Programme

Treatment of elderly and unfit patients with CRC

Ass. Prof. Fotios Loupakis, Prof. Hans Prenen and Ass. Prof. Joleen Hubbard discuss the Clinical Question: How to treat (or not) elderly colorectal cancer patients? Unfit: a relative concept

Go to Programme

Relevant papers discussed